NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free XLO Stock Alerts $1.06 +0.05 (+4.95%) (As of 10:08 AM ET) Add Compare Share Share Today's Range$1.02▼$1.0950-Day Range$0.55▼$1.5352-Week Range$0.49▼$3.40Volume13,381 shsAverage Volume1.02 million shsMarket Capitalization$36.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Xilio Therapeutics alerts: Email Address Xilio Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingAcquiring Shares$368,790 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.53) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector652nd out of 908 stocksPharmaceutical Preparations Industry300th out of 424 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Xilio Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.35% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently increased by 600.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XLO. Previous Next 2.9 News and Social Media Coverage News SentimentXilio Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week.Search Interest16 people have searched for XLO on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.MarketBeat Follows4 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have bought 78,533.26% more of their company's stock than they have sold. Specifically, they have bought $368,790.00 in company stock and sold $469.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.53) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWhat is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Xilio Therapeutics Stock (NASDAQ:XLO)Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More XLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XLO Stock News HeadlinesApril 4, 2024 | insidertrades.comGilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockApril 26, 2024 | americanbankingnews.comXilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest UpdateApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 25, 2024 | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Shares Up 1%April 17, 2024 | msn.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 12, 2024 | stocknews.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 2, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023April 1, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsApril 26, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 29, 2024 | marketwatch.comXilio Shares Take Flight Premarket After Gilead DealMarch 28, 2024 | investorplace.comWhy Is Xilio Therapeutics (XLO) Stock up 168% Today?March 28, 2024 | marketwatch.comXilio Therapeutics Plans Private Placement, Job CutsMarch 28, 2024 | markets.businessinsider.comXilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of JobsMarch 28, 2024 | globenewswire.comXilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingFebruary 28, 2024 | globenewswire.comXilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | morningstar.comXilio Therapeutics Inc XLOJanuary 31, 2024 | finance.yahoo.comXilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 8, 2024 | finance.yahoo.comXilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesDecember 28, 2023 | seekingalpha.comWerewolf Therapeutics: Still In The Race To Develop Next Generation CytokinesDecember 7, 2023 | finance.yahoo.comXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNovember 10, 2023 | msn.comXilio Therapeutics GAAP EPS of -$0.61November 9, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comPromising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio TherapeuticsNovember 3, 2023 | finance.yahoo.comXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsOctober 31, 2023 | finance.yahoo.comXilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingSeptember 27, 2023 | finance.yahoo.comXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 5, 2023 | markets.businessinsider.comXilio Therapeutics Appoints Katarina Luptakova As CMOSee More Headlines Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees81Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-126.55% Return on Assets-89.20% Debt Debt-to-Equity RatioN/A Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.75Miscellaneous Outstanding Shares34,470,000Free Float32,887,000Market Cap$34.81 million OptionableNot Optionable Beta-0.12 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Rene Russo BCPS (Age 49)Pharm.D., President, CEO & Director Comp: $888.49kMr. Kevin M. Brennan (Age 54)Senior VP of Finance & Accounting Mr. Christopher FrankenfieldChief Operating OfficerDr. Uli Bialucha Ph.D.Chief Scientific OfficerJulissa VianaVice President of Corporate CommunicationsMs. Stacey J. DavisChief Business OfficerDr. Katarina Luptakova M.D.Chief Medical OfficerDr. Scott Coleman Ph.D.Chief Development OfficerMore ExecutivesKey CompetitorsBriaCell TherapeuticsNASDAQ:BCTXUnicycive TherapeuticsNASDAQ:UNCYFortress BiotechNASDAQ:FBIOOcuphire PharmaNASDAQ:OCUPCara TherapeuticsNASDAQ:CARAView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 30,000 shares on 4/22/2024Ownership: 0.087%Gilead Sciences, Inc.Bought 485,250 shares on 4/2/2024Total: $368,790.00 ($0.76/share)Octagon Capital Advisors LPSold 533,500 shares on 2/15/2024Ownership: 6.481%Venture Fund Xi L.P. AtlasSold 733 sharesTotal: $469.12 ($0.64/share)Venture Fund Xi L.P. AtlasSold 1,566 sharesTotal: $1,362.42 ($0.87/share)View All Insider TransactionsView All Institutional Transactions XLO Stock Analysis - Frequently Asked Questions Should I buy or sell Xilio Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares. View XLO analyst ratings or view top-rated stocks. How have XLO shares performed in 2024? Xilio Therapeutics' stock was trading at $0.55 on January 1st, 2024. Since then, XLO stock has increased by 92.7% and is now trading at $1.06. View the best growth stocks for 2024 here. Are investors shorting Xilio Therapeutics? Xilio Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 0.3 days. Currently, 4.4% of the shares of the company are short sold. View Xilio Therapeutics' Short Interest. When is Xilio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XLO earnings forecast. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its quarterly earnings data on Monday, April, 1st. The company reported ($0.64) earnings per share (EPS) for the quarter. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include PFG Investments LLC (0.09%). Insiders that own company stock include Bain Capital Life Sciences Inv, Gilead Sciences, Inc, Rock Springs Capital Managemen and Venture Fund Xi LP Atlas. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XLO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
